Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC

Yanli Yao(Shanghai Ninth People's Hospital), Shuyang Sun(Shanghai Jiao Tong University)

Signal Transduction and Targeted Therapy

March 8, 2022

10.1038/s41392-022-00908-0

Cited by 37

Related Papers

A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis‐Targeting Chimeras Enhanced Immunotherapy

|Advanced Materials|2023|107